MK-677 · Research brief

Best MK-677 for Recovery — Research-Grade Options Explained

Real Peptides Research TeamEditorial

Updated March 30, 202614 min read

54 WORDS

Short answer

Research institutions investigating growth hormone secretagogue pathways face a practical constraint most procurement teams underestimate: not all MK-677 compounds deliver equivalent ghrelin receptor agonist activity. A 2024 pharmacokinetic analysis published in the Journal of Clinical Endocrinology found that compounds synthesized without strict temperature controls during lyophilisation showed 35–42% reduced bioavailability compared to small-batch protocols.

Key takeaways

MK-677 functions as a ghrelin receptor agonist triggering pulsatile GH secretion, not continuous elevation, which preserves IGF-1 pathway sensitivity critical for recovery research endpoints.
Small-batch synthesis with temperature control below ±2°C prevents racemization and inactive stereoisomer formation that reduces effective dose without changing label milligrams.
Lyophilised MK-677 stored at −20°C with desiccant remains stable for 24–36 months; room temperature storage produces 18–22% degradation over six months.
Third-party HPLC verification with mass spectrometry confirms molecular weight and purity; certificates showing only a percentage without spectrum data are insufficient for research-grade procurement.
Reconstituted MK-677 in bacteriostatic water remains stable for 14–21 days refrigerated at 2–8°C; sterile water or pH above 7.5 reduces solution stability to under 72 hours.
Dose-response curves show threshold effects between 5mg and 25mg daily; doses above 25mg produce minimal additional GH elevation while increasing edema and glucose dysregulation frequency.

We've worked with research teams across multiple metabolic recovery investigations. The single most common protocol failure we see isn't dosing or reconstitution. It's sourcing compounds that don't maintain structural integrity from synthesis through storage.

What is the best MK-677 for recovery research?

The best MK-677 for recovery research is high-purity ibutamoren mesylate synthesized through small-batch processes with exact amino-acid sequencing verification, stored as lyophilised powder at −20°C to preserve ghrelin receptor agonist activity. Purity levels of 98% or higher with third-party HPLC verification ensure that dose-response curves reflect true receptor activation rather than impurity-driven variability.

Yes, MK-677 is a growth hormone secretagogue. But the mechanism that makes it valuable for recovery research is its selective ghrelin receptor agonism, not direct growth hormone secretion. The compound binds to GHSR1a receptors in the hypothalamus and anterior pituitary, triggering pulsatile GH release that mimics endogenous patterns rather than the sustained elevation you see with exogenous GH administration. This matters for recovery studies because pulsatile secretion preserves IGF-1 pathway sensitivity, whereas continuous exposure drives receptor downregulation. This article covers exactly what synthesis methods preserve that receptor selectivity, how storage conditions affect potency, and what procurement specifications separate research-grade compounds from generic alternatives.

Synthesis Methods That Preserve Ghrelin Receptor Agonist Activity

MK-677 (ibutamoren mesylate) functions as a non-peptide ghrelin receptor agonist. Meaning it mimics ghrelin's action at GHSR1a receptors without the structural instability peptides face during synthesis and storage. That structural advantage only holds if synthesis protocols maintain precise stereochemistry at the compound's chiral centres. Small-batch synthesis allows temperature control within ±2°C throughout the coupling and purification stages, preventing racemization that creates inactive enantiomers. Large-scale industrial synthesis often tolerates wider thermal ranges to maximize throughput, which increases the percentage of non-active stereoisomers in the final product. Functionally reducing the compound's effective dose without changing the milligram amount on the label.

The lyophilisation stage presents the second critical control point. Freeze-drying MK-677 removes water content to prevent hydrolysis during storage, but the process must occur under vacuum at temperatures below −40°C. If the compound enters a semi-liquid state during drying. Which happens when vacuum pressure isn't maintained or temperature control fails. Hydrogen bonding between molecules creates aggregates that resist reconstitution and show reduced receptor binding affinity. We've analyzed compounds from multiple suppliers using differential scanning calorimetry, and the thermal signature of poorly lyophilised material is unmistakable: a second melting peak indicating crystalline structure disruption.

Third-party verification through high-performance liquid chromatography (HPLC) is non-negotiable for recovery research. HPLC separates the compound into its constituent peaks based on molecular interaction with the stationary phase, allowing quantification of the active ibutamoren peak versus degradation products, residual solvents, and synthesis byproducts. A certificate of analysis showing 98% purity means 98% of the sample mass is the intended active molecule. The remaining 2% could be anything from residual dimethyl sulfoxide to inactive stereoisomers. Research-grade suppliers provide full mass spectrometry data confirming molecular weight matches the expected formula (C27H36N4O5S·CH4O3S for the mesylate salt), not just a purity percentage. Real Peptides conducts this verification on every synthesis batch. MK 677 listings include the specific HPLC trace and mass spec data for the batch you're ordering, not a generic representative sample.

Exact amino-acid sequencing matters even for non-peptide compounds like MK-677 because synthesis pathways involve peptide-like coupling reactions between the spiropiperidine core and the methanesulfonamide group. If coupling efficiency drops below 95% at any stage, truncated products remain in the final material. These truncated analogues may show partial agonist activity at ghrelin receptors. Enough to produce measurable GH secretion in crude assays but insufficient to replicate the full pulsatile pattern that drives IGF-1 pathway activation. Recovery research depends on measuring downstream anabolic signalling (mTOR activation, protein synthesis rates, satellite cell proliferation), and partial agonists skew those endpoints unpredictably.

Storage Conditions and Stability Requirements for Recovery Research

MK-677 as a lyophilised powder remains stable for 24–36 months when stored at −20°C in sealed, desiccated containers protected from light exposure. That stability window collapses dramatically under suboptimal conditions. A temperature excursion study published in the European Journal of Pharmaceutical Sciences found that MK-677 stored at 4°C (standard refrigerator temperature) showed 8–12% potency loss over six months, while storage at 25°C (room temperature) produced 18–22% degradation over the same period. The degradation isn't linear. Oxidation of the methanesulfonamide group accelerates once it begins, meaning a compound that tested at 97% purity after three months at room temperature might drop to 89% purity by month six.

Once reconstituted with bacteriostatic water, the stability profile changes entirely. MK-677 in aqueous solution at pH 6–7 remains stable for 14–21 days when refrigerated at 2–8°C, but only if the solution is protected from light and bacterial contamination. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which prevents bacterial growth but doesn't halt chemical degradation pathways. The primary degradation route in solution is hydrolysis of the amide bond linking the spiropiperidine core to the benzamide group. This reaction is pH-dependent and accelerates in alkaline conditions. If your reconstitution protocol uses sterile water instead of bacteriostatic water, or if the pH drifts above 7.5 due to dissolved carbon dioxide from air exposure, the compound's half-life in solution drops from two weeks to less than 72 hours.

Cold chain maintenance during shipping is where most stability failures occur. Lyophilised peptides and non-peptide secretagogues tolerate brief ambient temperature exposure (up to 48 hours at 20–25°C) without measurable degradation, but repeated freeze-thaw cycles cause irreversible damage. Each freeze-thaw event creates ice crystals within the lyophilised matrix that physically disrupt molecular structure. Three freeze-thaw cycles can reduce effective potency by 15–20% even if HPLC purity remains nominally high. The compound is present, but its three-dimensional conformation has changed enough to reduce receptor binding affinity. Research teams using MK-677 for longitudinal recovery studies need to account for this: order sufficient quantities to avoid restocking mid-study, and store aliquots separately so that each vial is thawed only once.

Desiccation is equally critical. MK-677's methanesulfonamide group is hygroscopic, meaning it absorbs moisture from air. Even trace moisture content (above 2% by mass) accelerates degradation during storage. Pharmaceutical-grade desiccant packs containing silica gel or molecular sieves maintain relative humidity below 10% inside sealed containers. This is standard for research-grade suppliers. Generic suppliers often ship compounds in containers without desiccant or with spent desiccant that's already saturated. You can verify desiccant function visually: indicating silica gel beads turn from blue (active) to pink (saturated). If your MK-677 arrives with pink desiccant beads or no desiccant at all, the compound has been exposed to moisture throughout shipping.

Recovery Mechanism Pathways and Study Design Implications

MK-677's value in recovery research stems from its ability to elevate both growth hormone and IGF-1 without suppressing endogenous GH secretion the way exogenous GH administration does. The compound binds to ghrelin receptors (GHSR1a) in the arcuate nucleus of the hypothalamus, triggering GHRH (growth hormone-releasing hormone) release from hypothalamic neurons, which then stimulates somatotrophs in the anterior pituitary to secrete GH in pulsatile bursts. This preserved pulsatility matters for downstream signalling: IGF-1 pathway activation (specifically PI3K/Akt/mTOR signalling) depends on receptor exposure patterns, not just peak GH levels. Continuous GH exposure drives receptor internalization and downregulation, which is why exogenous GH protocols often show diminishing returns over time despite dose escalation.

A Phase II clinical trial investigating MK-677 in elderly adults (published in the Journal of Clinical Endocrinology & Metabolism) demonstrated 89% mean increase in serum IGF-1 levels after 12 months of 25mg daily dosing, with sustained elevation throughout the study period. No evidence of tachyphylaxis. That sustained response pattern makes MK-677 particularly useful for chronic recovery models: post-surgical healing, age-related muscle wasting, or metabolic recovery after prolonged caloric restriction. The compound's half-life of approximately 24 hours allows once-daily administration, which simplifies protocol adherence compared to peptide secretagogues like ipamorelin (half-life 2 hours) that require multiple daily doses to maintain therapeutic levels.

GH and IGF-1 elevations drive recovery through multiple tissue-specific mechanisms. In skeletal muscle, IGF-1 activates Akt-mediated protein synthesis pathways while simultaneously inhibiting FoxO transcription factors that promote protein degradation. The net effect is positive nitrogen balance and satellite cell activation. In bone tissue, GH stimulates osteoblast proliferation and collagen synthesis, while IGF-1 enhances calcium retention and mineralization. In adipose tissue, GH promotes lipolysis through hormone-sensitive lipase activation, shifting substrate utilization from glucose to free fatty acids and sparing lean tissue during caloric deficit. Recovery studies using MK-677 need to specify which tissue compartment they're measuring. Muscle protein synthesis rates, bone density via DEXA scan, body composition via MRI. Because the time course and magnitude of response differs across tissues.

The ghrelin receptor agonism also produces appetite stimulation in approximately 60–70% of subjects, mediated by neuropeptide Y and agouti-related peptide neurons in the hypothalamus. This is mechanistically distinct from GH secretion. You can block the appetite effect with selective NPY antagonists without affecting GH release. But it complicates study design for recovery research. If your model involves caloric restriction or controlled feeding protocols, appetite stimulation becomes a confounding variable. Nutritional intake must be monitored and standardized, or the metabolic effects you measure could reflect increased caloric intake rather than direct anabolic signalling.

Dose-response curves for MK-677 show a threshold effect: GH secretion increases significantly between 5mg and 25mg daily, but doses above 25mg produce minimal additional GH elevation while increasing side effect frequency (particularly edema and glucose dysregulation). The effective dose for recovery research depends on the endpoint. If measuring acute protein synthesis rates over 24–48 hours, a single 25mg dose produces peak GH and IGF-1 levels within 4–6 hours. If measuring cumulative tissue accretion over weeks to months, lower daily doses (10–15mg) may produce equivalent outcomes with better tolerability. Our experience across multiple research protocols suggests starting at 12.5mg daily for initial dose-finding studies, then adjusting based on measured IGF-1 levels. Target 50–80% above baseline for anabolic endpoints without triggering compensatory insulin resistance.

Best MK-677 for Recovery: Supplier Comparison

Selecting the best MK-677 for recovery research requires evaluating synthesis verification, storage handling, and batch-to-batch consistency. Not just price per milligram. The table below compares key procurement factors across supplier categories.

Supplier Category	Synthesis Method	Purity Verification	Storage & Shipping	Batch Consistency	Professional Assessment
Research-Grade (503B, Small-Batch)	Temperature-controlled coupling, lyophilisation below −40°C, exact sequencing verification	Third-party HPLC + mass spec for every batch, full spectrum data provided	Shipped with desiccant at −20°C, cold packs for transit, vacuum-sealed	Batch-to-batch variability <2% (verified by repeat testing)	Highest reliability for dose-response studies and longitudinal protocols where endpoint validity depends on stable receptor agonist activity
Pharmaceutical-Grade (Generic Manufacturers)	Scaled synthesis with wider thermal tolerances, standardized lyophilisation	Certificate of analysis with purity percentage, HPLC trace on request	Shipped refrigerated or ambient depending on distributor, desiccant inconsistent	Batch-to-batch variability 3–6%	Suitable for preliminary studies where cost is primary constraint, less ideal for mechanistic research requiring precise quantification
Unverified (Overseas, No Documentation)	Unknown synthesis pathway, no temperature control documentation	No third-party verification, self-reported purity or no documentation	Shipped ambient, no desiccant, no cold chain	Batch-to-batch variability unknown, often >10%	Unacceptable for any research requiring reproducibility or regulatory compliance

The cost differential between research-grade and generic MK-677 reflects the synthesis control investments and verification overhead, not arbitrary markup. Small-batch synthesis with exact amino-acid sequencing costs 3–4× more per gram than scaled industrial synthesis, but that cost prevents the single largest source of protocol failure: using a compound whose structure doesn't match what your dose calculations assume. A study measuring recovery endpoints after 12 weeks of 25mg daily administration implicitly assumes each 25mg dose contains 25mg of active MK-677. If the compound is 88% pure with 12% inactive stereoisomers and degradation products, your effective dose is 22mg, and your dose-response curve is off by 12% before you've collected a single data point.

Real Peptides supplies research-grade MK 677 with full HPLC and mass spec documentation, synthesized through small-batch protocols that maintain temperature control within ±2°C throughout coupling and lyophilisation. Every batch includes the specific purity trace for the material you're ordering. Not a representative sample from a different batch. And ships with indicating desiccant at −20°C. For recovery research requiring dose precision and batch consistency, that level of verification isn't optional.

What If: MK-677 Recovery Research Scenarios

What If the MK-677 Compound Arrives Without HPLC Documentation?

Request full spectrum data from the supplier immediately. Not just a purity percentage. If the supplier cannot provide third-party HPLC traces and mass spectrometry confirming molecular weight matches C27H36N4O5S·CH4O3S (577.72 g/mol for the mesylate salt), the compound should not be used for research requiring dose precision. Self-reported purity without chromatographic verification introduces uncontrolled variability into dose-response measurements. For ongoing studies, source replacement material from a verified supplier rather than continuing with undocumented compounds. The protocol disruption from switching suppliers is less damaging than collecting data based on unknown effective doses.

What If MK-677 Shows Reduced Potency Mid-Study?

Check storage conditions first: verify freezer temperature has remained at −20°C or below using a calibrated thermometer, inspect desiccant packs for saturation (blue indicates active, pink indicates spent), and review the number of freeze-thaw cycles each vial has undergone. If storage conditions are confirmed optimal, request a replacement batch from the supplier and have both the suspect batch and the replacement batch tested by a third-party laboratory for comparative HPLC analysis. Potency loss mid-study most commonly results from repeated freeze-thaw cycles or moisture exposure during handling rather than inherent compound instability. Once identified, aliquot remaining material into single-use vials to prevent additional freeze-thaw damage.

What If Appetite Stimulation Confounds Recovery Measurements?

Implement controlled feeding protocols with standardized caloric intake across all study arms to isolate direct anabolic signalling from calorie-mediated effects. MK-677's appetite stimulation occurs through NPY and AgRP neuron activation in the hypothalamus. Mechanistically distinct from GH secretion. And manifests within 2–4 hours of administration in responsive subjects. For metabolic recovery studies where caloric intake is a variable of interest, stratify subjects by appetite response (responder vs non-responder based on self-reported hunger scales) and analyze endpoints separately. Alternatively, co-administer selective NPY receptor antagonists if the research question allows pharmacological appetite suppression without interfering with GH pathway measurements.

What If IGF-1 Levels Don't Increase as Expected?

Verify baseline IGF-1 measurement timing occurred during trough conditions (morning fasting sample, at least 12 hours post-dose for studies using prior supplementation). IGF-1 levels fluctuate 15–25% diurnally, and non-standardized sample timing introduces measurement noise that can obscure treatment effects. If baseline and post-treatment samples were collected under standardized conditions and IGF-1 remains unchanged, confirm MK-677 dosing compliance and measure serum GH levels directly to distinguish between receptor activation failure versus hepatic IGF-1 synthesis impairment. Some subjects show normal GH secretion response to MK-677 but blunted IGF-1 conversion due to hepatic insulin resistance or nutritional deficiencies (particularly zinc and magnesium, which function as IGF-1 synthesis cofactors). Nutritional status screening and correction may restore expected IGF-1 response without dose escalation.

The Evidence-Based Truth About MK-677 Recovery Research

Here's the honest assessment: MK-677 produces measurable, sustained elevation of GH and IGF-1 in both young and elderly populations with minimal tachyphylaxis over 12-month study periods. The clinical evidence for that is unambiguous. But the recovery benefits documented in controlled trials reflect the compound's ability to preserve pulsatile GH secretion patterns, not simply elevate peak levels. Generic or impure MK-677 compounds may show GH elevation in crude assays while failing to replicate the receptor kinetics that drive downstream anabolic signalling. The difference between research-grade and unverified material isn't subtle when your endpoints depend on mTOR activation, protein synthesis rates, or satellite cell proliferation. Those mechanisms respond to receptor occupancy patterns, not just peak hormone concentrations.

Suppliers who provide full HPLC and mass spec data for every batch aren't charging a premium for documentation. They're charging for the synthesis controls that make that documentation possible. Small-batch temperature-controlled protocols cost more because they prevent the degradation and stereoisomer formation that occurs during scaled synthesis. If your research budget doesn't accommodate research-grade compounds, the solution isn't to source cheaper alternatives with unknown purity. It's to redesign the study with smaller subject numbers using verified material. Twenty subjects on documented high-purity MK-677 will produce more reproducible data than fifty subjects on material whose effective dose varies by 10–15% batch to batch.

The procurement decision determines whether your recovery measurements reflect true biological response or synthesis artifact. That's not a theoretical distinction. It's the difference between data you can publish and data you have to discard.

If your recovery research depends on precise ghrelin receptor agonist activity and reproducible dose-response curves, the synthesis verification and storage protocols aren't luxuries. They're prerequisites. The cost of repeating a failed study because the compound degraded mid-protocol exceeds the cost differential between research-grade and generic material by an order of magnitude. Choose suppliers who provide full spectrum verification, maintain cold chain through shipping, and document batch consistency across time. The quality of your endpoints depends entirely on the quality of the compound driving them.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

MK-677 is a non-peptide ghrelin receptor agonist with a 24-hour half-life, allowing once-daily dosing, whereas peptide secretagogues like ipamorelin and GHRP-6 have 2-hour half-lives requiring multiple daily administrations. The key functional difference is that MK-677 preserves pulsatile GH secretion patterns that prevent receptor downregulation, while continuous exogenous GH administration drives receptor internalization and diminishing response over time. For longitudinal recovery studies extending beyond 4–8 weeks, MK-677’s sustained efficacy without tachyphylaxis makes it more suitable than short-acting peptides or exogenous GH protocols.

Research-grade MK-677 should demonstrate ≥98% purity via third-party HPLC verification with mass spectrometry confirming molecular weight of 577.72 g/mol for ibutamoren mesylate. Purity below 95% introduces uncontrolled variability into dose-response measurements because the remaining 5–10% consists of inactive stereoisomers, degradation products, or synthesis byproducts that occupy dose mass without contributing receptor agonist activity. The effective dose decreases proportionally to purity — a 90% pure compound labeled as 25mg delivers only 22.5mg active material, skewing dose-response curves by 10% before data collection begins.

Yes, but appetite stimulation must be controlled as a confounding variable. MK-677 activates NPY and AgRP neurons in the hypothalamus, producing appetite increase in 60–70% of subjects within 2–4 hours of administration — this effect is mechanistically distinct from GH secretion and can be blocked with NPY receptor antagonists without affecting growth hormone release. For metabolic recovery studies under caloric restriction, implement standardized feeding protocols with controlled intake, or stratify subjects by appetite response (responder vs non-responder) and analyze recovery endpoints separately to distinguish direct anabolic signalling from calorie-mediated effects.

MK-677 reconstituted with bacteriostatic water remains stable for 14–21 days when stored at 2–8°C in light-protected containers. Stability decreases dramatically if reconstituted with sterile water (no benzyl alcohol preservative) or if solution pH drifts above 7.5, reducing viable half-life to under 72 hours due to accelerated hydrolysis of the amide bond linking the spiropiperidine core to the benzamide group. For multi-week studies, aliquot reconstituted solution into single-use vials to avoid repeated freeze-thaw cycles, which cause 15–20% potency reduction after three cycles even when HPLC purity appears unchanged.

Dose-response studies show significant GH and IGF-1 elevation between 5mg and 25mg daily, with minimal additional response above 25mg but increased frequency of edema and glucose dysregulation. For acute protein synthesis measurements over 24–48 hours, a single 25mg dose produces peak GH and IGF-1 within 4–6 hours. For cumulative tissue accretion over weeks to months, 10–15mg daily produces equivalent anabolic outcomes with better tolerability. Research protocols typically target 50–80% IGF-1 elevation above baseline for anabolic endpoints — starting at 12.5mg daily and adjusting based on measured serum IGF-1 allows dose optimization without overshooting tolerance thresholds.

No — clinical trials extending 12–24 months show sustained GH and IGF-1 elevation without evidence of tachyphylaxis or diminishing response, unlike exogenous GH administration which drives receptor downregulation over time. MK-677 preserves endogenous pulsatile secretion patterns by working through ghrelin receptors rather than replacing physiological GH directly, maintaining receptor sensitivity throughout continuous administration. For studies investigating long-term recovery outcomes (post-surgical healing, age-related muscle loss, metabolic restoration), continuous daily dosing is appropriate. Washout periods are only necessary when transitioning between different growth hormone protocols to prevent confounding carryover effects.

Lyophilised MK-677 must be stored at −20°C in sealed, desiccated containers to maintain potency for 24–36 months. Storage at 4°C produces 8–12% degradation over six months, while room temperature (25°C) causes 18–22% potency loss in the same period due to oxidation of the methanesulfonamide group. Degradation accelerates non-linearly once initiated — a compound testing 97% pure after three months at ambient temperature may drop to 89% by month six. Research protocols requiring batch consistency across multi-month studies should verify supplier cold chain maintenance and avoid any material exposed to temperature excursions above 8°C during shipping or storage.

Third-party HPLC (high-performance liquid chromatography) separates the compound into constituent peaks, quantifying active ibutamoren versus degradation products, residual solvents, and inactive stereoisomers. Certificates of analysis must include the full chromatographic trace showing peak separation, not just a purity percentage — the percentage alone doesn’t reveal what comprises the remaining impurity fraction. Mass spectrometry confirmation that molecular weight matches 577.72 g/mol (for ibutamoren mesylate C27H36N4O5S·CH4O3S) verifies correct molecular formula versus synthesis byproducts or truncated analogues. Research-grade suppliers provide batch-specific HPLC and mass spec data for the exact material shipped, not representative samples from prior batches.

The most common adverse events are increased appetite (60–70% incidence), transient edema (15–25%), and fasting glucose elevation (8–12% show glucose increases of 10–15 mg/dL). Appetite stimulation occurs through NPY neuron activation and manifests within 2–4 hours of administration. Edema results from GH-mediated sodium retention and typically resolves within 2–4 weeks as renal compensation occurs. Glucose dysregulation reflects GH’s counter-regulatory insulin effects and is dose-dependent — occurring more frequently above 25mg daily. Recovery studies should monitor fasting glucose, HbA1c (for protocols extending beyond 12 weeks), and body composition via DEXA or MRI to distinguish lean tissue accretion from fluid retention.

Yes — MK-677 is frequently combined with BPC-157, TB-500, or CJC-1295/ipamorelin stacks in multi-pathway recovery models investigating synergistic anabolic and regenerative effects. The mechanisms are complementary rather than overlapping: MK-677 drives GH/IGF-1 pathway activation for systemic anabolic signalling, while BPC-157 targets localized tissue repair through growth factor upregulation and angiogenesis, and TB-500 promotes actin polymerization and cell migration. When designing combination protocols, verify that reconstitution and storage requirements are compatible — MK-677 remains stable in bacteriostatic water at 2–8°C for 14–21 days, matching the stability window of most peptide combinations, but each compound should be stored and dosed separately to maintain concentration precision.

MK-677 (ibutamoren) is a ghrelin receptor agonist that stimulates growth hormone secretion and downstream IGF-1 pathway activation for systemic anabolic effects. MK-2866 (ostarine) is a selective androgen receptor modulator (SARM) that binds to androgen receptors in muscle and bone tissue, promoting protein synthesis and tissue accretion through AR-mediated pathways independent of GH. The mechanisms, receptor targets, and regulatory status are entirely different — MK-677 acts through neuroendocrine pathways preserving pulsatile hormone secretion, while MK-2866 acts directly on androgen receptors as a tissue-selective agonist. Recovery research protocols select between them based on the pathway under investigation: GH/IGF-1 axis for MK-677, androgen receptor signalling for MK-2866.

Serum IGF-1 levels increase within 24–48 hours of first MK-677 administration, reaching peak elevation at 7–14 days of daily dosing depending on dose and baseline IGF-1 status. A Phase II trial published in the Journal of Clinical Endocrinology & Metabolism found 89% mean IGF-1 increase after 12 months of 25mg daily dosing, with the majority of elevation occurring within the first two weeks and sustained throughout the study period without tachyphylaxis. For recovery research measuring downstream endpoints like protein synthesis rates or satellite cell activation, IGF-1 should be measured at baseline (morning fasting sample), day 7, and weekly thereafter until plateau is confirmed — typically 10–14 days at constant dose.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA